Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Active Biotech, Ipsen Present OS Data From Tasquinimod Phase II Study In CRPC

Active Biotech (ATVBF.PK) and Ipsen presented overall survival, or OS, data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer, or CRPC.

The intention-to-treat analysis showed median overall survival times of 33.4 vs. 30.4 months in favor of tasquinimod, longer than previously reported in this metastatic prostate cancer population. A stronger trend for survival benefit is observed in patients with bone metastases. This phase II clinical trial was designed to test the safety and efficacy of tasquinimod.

Noteworthy, 41 patients crossed-over from placebo to tasquinimod. Besides, there were imbalances in baseline prognostic factor in favor of the placebo arm. These were addressed with a multivariate analysis of known CRPC prognostic factors. It showed a statistically significant OS advantage for tasquinimod treated patients with a hazard ratio of 0.64, a decrease of around 40% in the instantaneous risk of event (death), accompanied by improvement in progression-free survival.

Click here to receive FREE breaking news email alerts for Active Biotech and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.